Drugs / Ranquilon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05586789 | Oct → Nov 2022 | adjustment disorder, anxiety, neurocirculatory asthenia | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06843044 | Jan 2025 → Dec 2027 expected | adjustment disorder, anxiety, neurocirculatory asthenia | Valenta Pharm JSC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ranquilon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05586789 ↗ |